Founded in 2002, Celltrion is a global biopharmaceutical company from South Korea that pioneered the world’s first antibody biosimilar. With world-class production capabilities and a quality control system that delivers a production success rate of over 99%, Celltrion ensures the consistent and reliable supply of high-quality biologics.
Driven by its mission to create a healthier tomorrow where no patients are left untreated, Celltrion operates a robust and ever-expanding global network, collaborating with a wide range of international partners and numerous entities, and has achieved regulatory approvals in over 100 countries, including from the U.S. FDA and EMA.
Celltrion is also committed to research and development, investing about 20% of its annual revenue into R&D. The company aims to commercialize 22 products by 2030, spanning key therapeutic areas including immunology, oncology, and other emerging indications.
By combining innovation, global partnerships, and scalable production capabilities, Celltrion remains dedicated to improving the health and well-being of patients around the world.
Role within INTERCEPT
Celltrion, as an IHI JU private member and contributing partner, will contribute to the INTERCEPT project through financial support for the organizing and conducting of the interventional clinical trial HALT-CD (WP 4). Celltrion’s contribution reflects its commitment to addressing the lack of validated biomarkers in Crohn’s disease and supporting meaningful progress toward earlier diagnosis, improved treatments and better outcomes for patients.
Main contacts
Dr. Young Nam Lee
Head of Global Medical Affairs Department
Dr. Soyeon Park
MSL Team Leader, Global Medical Affairs
Shinyoung Park
MSL, Global Medical Affairs